BCD Regimen in Newly Diagnosed Idiopathic Multicentric Castleman's Disease (iMCD)

Idiopathic Multicentric Castleman's Disease Clinical Trial

Official title: Bortezomib, Cyclophosphamide and Dexamethasone (BCD) in Newly Diagnosed Idiopathic Multicentric Castleman's Disease (iMCD) : a Prospective, Single-center, Single-arm, Phase-II Pilot Trial

Status Recruiting

Clinical Trial Summary

To explore the effectiveness and safety of bortezomib, cyclophosphamide and dexamethasone (BCD regimen) in newly diagnosed idiopathic Multicentric Castleman's disease (iMCD) patients.

Clinical Trial Description

This will be a single center, open-labeled, single arm, phase-II pilot study. The treatment and the response evaluation phase will last from the time of enrollment up to 21 months (evaluation will be carried out every 3 months in the first 9 months and every 6 months from Month 9 to Month 21). The maintenance and follow-up phase to assess for progression of disease will last from 21 months to 45 months after enrollment (evaluation will be carried out every 12 months). The total study duration will be 4 years after the last patient starts study medication. ;

Related Conditions & MeSH terms

• Castleman Disease
• Idiopathic Multicentric Castleman's Disease

• NCT number: NCT03982771
• Study type: Interventional
• Source: Peking Union Medical College Hospital
• Status: Recruiting
• Phase: Phase 2
• Start date: January 1, 2019
• Completion date: January 1, 2023